Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    INCAGN2385-201
Previous Study | Return to List | Next Study

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04370704
Recruitment Status : Recruiting
First Posted : May 1, 2020
Last Update Posted : December 19, 2020
Sponsor:
Information provided by (Responsible Party):
Incyte Corporation

Brief Summary:
The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.

Condition or disease Intervention/treatment Phase
Melanoma Drug: INCAGN02385 Drug: INCAGN02390 Drug: INCMGA00012. Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
Actual Study Start Date : July 28, 2020
Estimated Primary Completion Date : July 26, 2023
Estimated Study Completion Date : July 26, 2023

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma

Arm Intervention/treatment
Experimental: Phase 1 Part 1
Part 1 will confirm the safety of INCAGN02385 and INCAGN02390 when used in combination. INCAGN02385 will be administered first intravenously followed by INCAGN02390.
Drug: INCAGN02385
INCAGN02385 administered intravenously

Drug: INCAGN02390
INCAGN02390 administered intravenously

Experimental: Phase 1 Part 2
Part 2 will confirm the safety of the triple combination of INCAGN02385 + INCAGN02390 + INCMGA00012, following confirmation of the safety of the doublet in Part 1. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012.
Drug: INCAGN02385
INCAGN02385 administered intravenously

Drug: INCAGN02390
INCAGN02390 administered intravenously

Drug: INCMGA00012.
INCMGA00012 administered intravenously

Experimental: Phase 2
Phase 2 will determine preliminary efficacy and proof of concept for the combination of INCAGN02385 + INCAGN02390 + INCMGA00012. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012
Drug: INCAGN02385
INCAGN02385 administered intravenously

Drug: INCAGN02390
INCAGN02390 administered intravenously

Drug: INCMGA00012.
INCMGA00012 administered intravenously




Primary Outcome Measures :
  1. Phase 1 and 2 : Participants with treatment-emergent adverse events (TEAE) [ Time Frame: 28 days after end of study approximately 24 months ]
    TEAE is defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug

  2. Phase 2 : Objective Response Rate [ Time Frame: Every 8 weeks for first 12 months, and every 12 weeks until disease progression; aprroximately 24 months ]
    Defined as the percentage of participants having a Complete Response or Partial Response, will be determined by investigator assessment of radiographic disease assessments per RECIST v1.1.

  3. Phase 2 : Duration of Response [ Time Frame: Every 8 weeks for first 12 months, and every 12 weeks until disease progression; aprroximately 24 months ]
    Defined as the time from earliest date of disease response (CR or PR) until earliest date of disease progression, as determined by investigator assessment of radiographic disease per RECIST v1.1, or death from any cause, if occurring sooner than progression.

  4. Phase 2 : Disease Control Rate [ Time Frame: Every 8 weeks for first 12 months, and every 12 weeks until disease progression; aprroximately 24 months ]
    Defined as percentage of participants having CR, PR, or SD as best on-study response


Secondary Outcome Measures :
  1. Phase 1 : Objective Response Rate [ Time Frame: Every 8 weeks for first 12 months, and every 12 weeks until disease progression; aprroximately 24 months ]
    Defined as the percentage of participants having a Complete Response or Partial Response, will be determined by investigator assessment of radiographic disease assessments per RECIST v1.1.

  2. Phase 1 : Progression Free Survival [ Time Frame: Every 8 weeks for first 12 months, and every 12 weeks until disease progression; aprroximately 24 months ]
    Defined as the time from date of first dose of study treatment until the earliest date of disease progression, as determined by investigator assessment of objective radiographic disease per RECIST v1.1.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women, aged 18 or older.
  • Willingness to provide written informed consent for the study.
  • Phase 1: Participants with locally advanced or metastatic solid tumors for which a PD-1 inhibitor is indicated (locally advanced disease must not be amenable to resection with curative intent) that have failed a PD-1/PD-L1 inhibitor therapy.

    a. PD should be based on imaging done at least 4 weeks apart.

  • Phase 2: Participants with histologically confirmed recurrent Stage III and Stage IV melanoma who relapsed during therapy with anti-PD-1 given as adjuvant therapy.

    1. Participants should have no more than one prior therapy given as adjuvant treatment.
    2. Participants in Stage 1 (n = 13) and Stage 2 (n = 21) of Phase 2 should have documented LAG-3 positive expression (≥ 5%) by IHC.
    3. Participants should be documented BRAF mutation negative.
  • Participants must have fresh biopsy available after completing adjuvant therapy or be willing and able to safely undergo pretreatment tumor biopsies (core or excisional).
  • ECOG performance status 0 or 1.
  • Willingness to avoid pregnancy or fathering children

Exclusion Criteria:

  • Laboratory and medical history parameters outside the protocol-defined range.
  • Known hypersensitivity or severe reaction to any component of the study drugs or formulation components ) within 14 days before study Day 1.
  • Administration of colony-stimulating factors within 14 days before study Day 1.
  • Receipt of a live vaccine within 30 days of planned start of study treatment.
  • Receipt of anticancer medications or investigational drugs within the following intervals before the first administration of study treatment
  • Phase 1:

    1. ≤ 14 days for chemotherapy, targeted small molecule therapy, or radiation therapy. Participants must also not require chronic use of corticosteroids and must not have had radiation pneumonitis as a result of treatment. A 1-week washout is permitted for palliative radiation to non-CNS disease with medical monitor approval.
    2. ≤ 14 days and resolution of all associated toxicities for prior immunotherapy or persistence of active cellular therapy c. < 14 days for prior PD-1 pathway-targeted agents (for Phase 1 and Phase 2).

    d. ≤ 28 days for a prior mAb used for anticancer therapy with the exception of PD-1 pathway-targeted agents and denosumab.

    e. ≤ 7 days for immune-suppressive-based treatment for any reason. f. ≤ 28 days or 5 half-lives (whichever is longer) before the first dose for all other investigational agents or devices. For investigational agents with long half-lives (eg, > 5 days), enrollment before the fifth half-life requires medical monitor approval.

    g. Has not recovered to ≤ Grade 1 from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting therapy.

  • Phase 2:

    1. Receipt of any anticancer medication other than adjuvant anti-PD-1 therapy.
    2. Receipt of PD-1 pathway-targeted inhibitors within 14 days before the first administration of study treatment.
    3. Unknown LAG-3 status or LAG-3 positive > 0% but < 5%

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04370704


Contacts
Layout table for location contacts
Contact: Incyte Corporation Call Center (US) 1.855.463.3463 medinfo@incyte.com
Contact: Incyte Corporation Call Center (ex-US) +800 00027423 eumedinfo@incyte.com

Locations
Layout table for location information
United States, California
The Angeles Clinic and Research Institute Recruiting
Los Angeles, California, United States, 90025
United States, New Jersey
John Theurer Cancer Center, Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
United States, North Carolina
Carolina Bio Oncology Recruiting
Huntersville, North Carolina, United States, 28078
United States, Pennsylvania
Hillman Cancer Center Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
Incyte Corporation
Layout table for additonal information
Responsible Party: Incyte Corporation
ClinicalTrials.gov Identifier: NCT04370704    
Other Study ID Numbers: INCAGN 2385-201
First Posted: May 1, 2020    Key Record Dates
Last Update Posted: December 19, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Incyte Corporation:
PD-1 Inhibitors
INCAGN02385
INCAGN02390
INCMGA00012
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas